Literature DB >> 8575033

Synthesis of carboxymethylpullulan-peptide-doxorubicin conjugates and their properties.

H Nogusa1, T Yano, S Okuno, H Hamana, K Inoue.   

Abstract

The amino group of doxorubicin (DXR) was found to be bound to the carboxyl group of carboxymethylpullulan (CMPul) either directly or through tetrapeptide spacers, including Gly-Gly-Phe-Gly, Gly-Phe-Gly-Gly and Gly-Gly-Gly-Gly. These conjugates had DXR contents of 6.1-7.1%, with the degree of substitution of carboxymethyl groups being 0.6 per sugar moiety. These conjugates associate in phosphate-buffered saline (PBS) (pH 7.4), forming micelles with hydrophobic DXR inside and hydrophilic CMPul on the outside. The amounts of DXR released from the conjugates in the presence of rat liver lysosomal enzymes were determined by HPLC. The rate of the drug release differed among the conjugates tested. CMPul-DXR conjugate bound through Gly-Gly-Phe-Gly released 35% of its DXR over 24 h. On the other hand, CMPul-DXR conjugate without spacer released no free DXR. The antitumor effect of each conjugate in rats bearing Walker 256 was studied by monitoring the tumor weights after a single intravenous injection. Compared with DXR, CMPul-DXR conjugates bound through Gly-Gly-Phe-Gly and Gly-Phe-Gly-Gly spacers significantly suppressed the tumor growth, while CMPul-DXR conjugate bound through Gly-Gly-Gly-Gly showed less antitumor effect than DXR. CMPul-DXR conjugate bound through Gly-Gly-Gly-Gly showed less antitumor effect than DXR. CMPul-DXR conjugate without spacer showed no in vivo antitumor effect even at a dose equivalent to as much as 20 mg/kg of DXR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8575033     DOI: 10.1248/cpb.43.1931

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  4 in total

1.  Enhanced accumulation of sialyl Lewis X-carboxymethylpullulan conjugate in acute inflammatory lesion.

Authors:  K Horie; M Sakagami; K Kuramochi; K Hanasaki; H Hamana; T Ito
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

2.  Evaluation of carboxymethylpullulan as a novel carrier for targeting immune tissues.

Authors:  K Masuda; M Sakagami; K Horie; H Nogusa; H Hamana; K Hirano
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

Review 3.  Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting.

Authors:  Khaled Greish; Jun Fang; Takao Inutsuka; Akinori Nagamitsu; Hiroshi Maeda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Improved in vivo antitumor efficacy and reduced systemic toxicity of carboxymethylpullulan-peptide-doxorubicin conjugates.

Authors:  H Nogusa; H Hamana; N Uchida; R Maekawa; T Yoshioka
Journal:  Jpn J Cancer Res       Date:  2000-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.